{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_9512212_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"195-607-614-738-492"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10827,"type":"PATENT","title":"University of Arizona - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8025,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8279,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: Univ* AND Arizona;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4153
Search Applicants and Owners separately: Arizona AND State AND Univ*;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2581
Search Applicants and Owners separately: Univ* AND Arizona;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4153
Search Applicants and Owners separately: Arizona AND State AND Univ*;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2581
(a) a first scFv that is specific for soluble Aβ, wherein the first scFv is H1v2 anti-Ab40 (SEQ ID NO: 6), H1v3 anti-Ab40 (also called D9antiAb40) (SEQ ID NO: 7), or C1 antiAb40 (SEQ ID NO: 8), and\n
(b) a second scFv that specifically activates a classical complement pathway component or directly activates microglial cells, wherein the scFv fragment specifically binds to C1q."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["An antibody construct comprising the bispecific antibody fragment of claim 1, further comprising a second bispecific antibody fragment."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The bispecific antibody fragment of claim 1, further comprising a (Gly4-Ser)3 linker (SEQ ID NO: 1) operably linked between the first and second scFvs."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The bispecific antibody fragment of claim 3, further comprising a poly-His tail operably linked to either the first or second scFvs."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The bispecific antibody of claim 1, wherein\n
(a) the first scFv is an H1 scFv specific for β-amyloid, wherein the first scFv has an amino-terminus and a carboxy-terminus, and\n
(b) the second scFv is an scFv specific for C1q, wherein the second scFv has an amino-terminus and a carboxy-terminus, and wherein the bispecific antibody further comprises\n
(c) a (Gly4Ser)3 peptide linker (SEQ ID NO: 1) operably linking the carboxy-terminus of the first scFv to the amino-terminus of the second scFv."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The bispecific antibody of claim 1, further comprising a gIII signal sequence operably linked to the amino-terminus of the first scFv."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The bispecific antibody of claim 1, further comprising a c-myc tag operably linked to the carboxy-terminus of the second scFv."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The bispecific antibody of claim 7, further comprising a (His)6 tag (SEQ ID NO: 2) operably linked to the c-myc tag."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid encoding the bispecific antibody of claim 1."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["An expression cassette comprising\n
the nucleic acid sequence of claim 9, and\n
a promoter."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A vector comprising the expression cassette of claim 10."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A cell comprising the nucleic acid of claim 9."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A therapeutic composition comprising the bispecific antibody of claim 1, in combination with a physiologically-acceptable, non-toxic vehicle."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A method of clearing aggregated and soluble Aβ comprising administering the bispecific antibody of claim 1."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the aggregated and soluble Aβ is in a cell."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15 wherein aggregated and soluble Aβ is in brain tissue."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein the brain tissue is in a mammal."],"number":17,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}